K
Kenji Kosaka
Researcher at Yokohama City University
Publications - 274
Citations - 20373
Kenji Kosaka is an academic researcher from Yokohama City University. The author has contributed to research in topics: Dementia with Lewy bodies & Dementia. The author has an hindex of 51, co-authored 274 publications receiving 18520 citations. Previous affiliations of Kenji Kosaka include Hochschule Hannover & Max Planck Society.
Papers
More filters
Journal ArticleDOI
The splicing regulatory protein p18SRP is down-regulated in Alzheimer's disease brain.
Klaus Heese,Masako Fujita,Hiroyasu Akatsu,Takayuki Yamamoto,Kenji Kosaka,Yasuo Nagai,Tohru Sawada +6 more
TL;DR: It is demonstrated here that the new putative splicing regulatory protein p18SRP is a lysine-rich zinc finger domain-containing protein that interacts with the serine-arginine (SR)-rich splicing Regulatory protein SRrp86.
Journal ArticleDOI
Autopsy case of concurrent Huntington's disease and neurofibromatosis type 1
Ito Kawakami,Ito Kawakami,Omi Katsuse,Naoya Aoki,Takashi Togo,Kyoko Suzuki,Daisuke Isojima,Daizo Kondo,Eizo Iseki,Kenji Kosaka,Haruhiko Akiyama,Yoshio Hirayasu +11 more
TL;DR: An autopsy case of concurrent Huntington's disease (HD) and neurofibromatosis type 1 (NF1), also known as von Recklinghausen's disease, is reported, and the first study in which occurrence of polyglutamine inclusions was confirmed on post‐mortem examination.
Journal ArticleDOI
Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Toshinari Odawara,Kazuko Hasegawa,Ritsuko Kajiwara,Hisao Takeuchi,Masaaki Tagawa,Kenji Kosaka,Miho Murata +6 more
TL;DR: In this article, the authors evaluated the long-term efficacy and safety of zonisamide, an antiepileptic agent, in dementia with Lewy bodies (DLB), in a clinical trial with 12 weeks, randomized, placebo-controlled, double-blind, and subsequent 40 week, open-label, extension periods.
Journal ArticleDOI
A novel alternative splice variant of nicastrin and its implication in Alzheimer disease.
Noriaki Mitsuda,Hidehisa Yamagata,Wangtao Zhong,Mamoru Aoto,Hiroyasu Akatsu,Natsuko Uekawa,Kouzin Kamino,Keiko Taguchi,Takayuki Yamamoto,Mitsuo Maruyama,Kenji Kosaka,Masatoshi Takeda,Ikuko Kondo,Tetsuro Miki +13 more
TL;DR: The expression of NCSTN-DeltaE16 transcript may confer some additional risk for developing Alzheimer disease beyond the risk due to ApoE-epsilon4 allele.